Amyloid exacerbates tau and alpha‐synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model
Alzheimer's & Dementia · 2026
DOI: 10.1002/alz.71639 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Benjamin E Rabichow und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: alpha-Synuclein, tau Proteins, Neuroinflammatory Diseases, Mixed Dementias. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS Lewy Body Dementia Center Without Walls, Translational Genomics Research Institute (TGen) Foundation, NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Neurodegenerative diseases often involve overlapping alpha‐synuclein (asyn), amyloid beta, and tau proteinopathies, yet the mechanisms, impact, and directionality of their interactions remain unclear. METHODS We induced brain‐wide neuronal asyn/tau pathologies via viral expression of wild‐type asyn, mutant asyn E46K , mutant tau A152T , or both asyn E46K /tau A152T in adult amyloidosis knock‐in mice and controls, either post‐plaque deposition (6 months old) or pre‐plaque (3 months old). Open‐field behavior was assessed baseline and 3 and 6 months post‐transduction, followed by neuropathology and neuroinflammation analyses. RESULTS Post‐plaque induction in amyloid mice increased asyn/tau total and phosphorylated levels and exacerbated amyloid‐related hyperlocomotion/anxiety. Pre‐plaque induction produced robust phosphorylated pathologies irrespective of amyloid, while causing similar amyloid‐dependent behavioral synergy. Tau pathology drove LGALS3 + inflammatory glial responses in white‐matter fibers. DISCUSSION Amyloid context gates vulnerability, with certain synergies manifesting across stages. White‐matter gliosis is a novel mechanism of tau A152T risk. Together, our data argue for the development of stage‐aware, multitarget interventions and biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Phoenix, Arizona, USA.
- Department of Neuroscience, Mayo Clinic, Phoenix, Arizona, USA.
- Center for Accelerated Nanotherapeutics, Translational Genomics Research Institute, Phoenix, Arizona, USA.
ORCID-Profile: Benjamin E Rabichow
Förderung
- NINDS Lewy Body Dementia Center Without Walls
- Translational Genomics Research Institute (TGen) Foundation
- NIH HHS
- National Institutes of Health
Zitieren
APA
Rabichow, B. E., Nixon, L., Tallant, L. E., Gibson, K. A., Nascari, D. G., Barnett, J. H., Massa, N., & Fryer, J. D. (2026). Amyloid exacerbates tau and alpha‐synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71639
Vancouver
Rabichow BE, Nixon L, Tallant LE, Gibson KA, Nascari DG, Barnett JH, et al. Amyloid exacerbates tau and alpha‐synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71639
BibTeX
@article{Rabichow2026,
author = {Rabichow, Benjamin E and Nixon, Lacey and Tallant, Lauren E and Gibson, Katelin A and Nascari, David G and Barnett, J Hudson and Massa, Nashali and Fryer, John D},
title = {Amyloid exacerbates tau and alpha‐synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model},
journal = {Alzheimer's & Dementia},
year = {2026},
doi = {10.1002/alz.71639}
}
EUVIMED